Observational studyMedicine2016
Prevalence, awareness, and treatment of anemia in Chinese patients with nondialysis chronic kidney disease: First multicenter, cross-sectional study.
Observational study in Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 66 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Pooled it
- Risk Factors for Anemia in Patients with Chronic Renal Failure: A Systematic Review and Meta-Analysis.Ethiopian journal of health sciences · 2020Pooled it
- Effects of Jianpi Bushen Therapy for Treatment of CKD Anemia: A Meta-Analysis of Randomized Controlled Trials.Frontiers in pharmacology · 2020Pooled it
- Long-term safety and effectiveness of roxadustat in Chinese patients with chronic kidney disease-associated anemia: The ROXSTAR registry.Chinese medical journal · 2025Trial
- [Effect of Qingshen Granules on inflammation/hepcidin axis and iron metabolism in patients with renal anemia: a single-center, randomized controlled trial].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2019Trial
- Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2017Trial
- Plasma Erythropoietin Levels and Anemia in Vietnamese Patients With Type 2 Diabetes and Chronic Kidney Disease: 2018-2019.Health science reports · 2026Article
- Interstitial Fibrosis Severity Is Not Independently Associated with Anemia in Biopsy-Proven Primary Glomerulonephritis: A Nationwide Registry Analysis.Medicina (Kaunas, Lithuania) · 2026Article
- Effect of Roxadustat and Erythropoietin on Glycated Hemoglobin of Non-Dialysis Type 2 Diabetic Nephropathy Anemia Patients.Biomedicines · 2026Article
- Anemia and risk of ischemic heart disease among adults with hypertension in Thailand.BMC research notes · 2026Article
- Analysis of gut microbiota and fecal/plasma short-chain fatty acids in non-dialysis renal anemia patients: associations with clinical parameters.Frontiers in microbiology · 2026Article
- Analysis of red blood cell lifespan and associated influencing factors in anemic dialysis patients.Renal failure · 2025Article
- The impaired white-matter structural network mediates the relationship between the glymphatic system and emotional abnormalities in patients with chronic kidney disease.Quantitative imaging in medicine and surgery · 2025Article
- Disease-modifying effects of iron deficiency in mouse models of chronic renal failure.Blood red cells & iron · 2025Article
- Anemia, iron metabolism, and anemia medication habits in patients undergoing maintenance hemodialysis and peritoneal dialysis are different: a multicenter investigation.Clinical and experimental nephrology · 2025Article
- Sex- and Stage-Specific Predictors of Anemia in Chronic Kidney Disease: A Retrospective Cohort Study.Journal of clinical medicine · 2025Article
- Randomized Trial of Lower-Dose Roxadustat Efficacy and Safety in Non-Dialysis-Dependent CKD-Associated Anemia.Kidney international reports · 2025Article
- Anemia in diabetes mellitus: Pathogenetic aspects and the value of early erythropoietin therapy.Metabolism open · 2025Review
- EPO-Mimetic Peptide Pegmolesatide Therapy for Pure Red Cell Aplasia in a Patient with Non-dialysis-dependent Type 1 Diabetic Nephropathy: A Case Report.Kidney medicine · 2025Article
- Relationship of sKlotho with hemoglobin level in patients undergoing maintenance hemodialysis: a case-control study.Therapeutic advances in chronic disease · 2025Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This was the first multicenter, cross-sectional survey to assess the prevalence of anemia, patient awareness, and treatment status in China. Data of patients with chronic kidney disease (CKD; age, 18-75 years; both out- and inpatients) from 25 hospitals in Shanghai, seeking medical treatment at the nephrology department, were collected between July 1, 2012 and August 31, 2012. The prevalence, awareness, and treatment of anemia in patients with nondialysis CKD (ND-CKD) were assessed. Anemia was defined as serum hemoglobin (Hb) levels ≤12 g/dL in women and ≤13 g/dL in men. A total of 2420 patients with ND-CKD were included. Anemia was established in 1246 (51.5%) patients: 639 (51.3%) men and 607 (48.7%) women. The prevalence of anemia increased with advancing CKD stage (χtrend = 675.14, P < 0.001). Anemia was more prevalent in patients with diabetic nephropathy (68.0%) than in patients with hypertensive renal damage (56.6%) or chronic glomerulonephritis (46.1%, both P < 0.001). Only 39.8% of the anemic patients received treatment with erythropoietin and 27.1% patients received iron products; furthermore, 22.7% of the patients started receiving treatment when their Hb level reached 7 g/dL. The target-achieving rate (Hb at 11-12 g/dL) was only 8.2%. Of the 1246 anemia patients, only 7.5% received more effective and recommended intravenous supplementation. Anemia is highly prevalent in patients with ND-CKD in China, with a low target-achieving rate and poor treatment patterns. The study highlights the need to improve multiple aspects of CKD management to delay the progression of renal failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.